These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22498572)

  • 21. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
    Licitra L; Mesia R; Rivera F; Remenár É; Hitt R; Erfán J; Rottey S; Kawecki A; Zabolotnyy D; Benasso M; Störkel S; Senger S; Stroh C; Vermorken JB
    Ann Oncol; 2011 May; 22(5):1078-1087. PubMed ID: 21048039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Khuri FR
    Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
    Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
    Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review.
    Winquist E; Agbassi C; Meyers BM; Yoo J; Chan KKW;
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):29. PubMed ID: 28376866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Péron J; Ceruse P; Lavergne E; Buiret G; Pham BN; Chabaud S; Favier B; Girodet D; Zrounba P; Ramade A; Fayette J
    Anticancer Drugs; 2012 Oct; 23(9):996-1001. PubMed ID: 22643048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    Bauml J; Seiwert TY; Pfister DG; Worden F; Liu SV; Gilbert J; Saba NF; Weiss J; Wirth L; Sukari A; Kang H; Gibson MK; Massarelli E; Powell S; Meister A; Shu X; Cheng JD; Haddad R
    J Clin Oncol; 2017 May; 35(14):1542-1549. PubMed ID: 28328302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
    Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
    Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
    Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
    J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
    J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Afatinib in squamous cell carcinoma of the head and neck.
    Specenier P; Vermorken J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
    Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
    J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients treated with palliative weekly paclitaxel plus cetuximab in recurrent head and neck cancer after failure of platinum-based therapy.
    Sosa AE; Grau JJ; Feliz L; Pereira V; Alcaraz D; Muñoz-García C; Caballero M
    Eur Arch Otorhinolaryngol; 2014 Feb; 271(2):373-8. PubMed ID: 23644939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.
    León X; Hitt R; Constenla M; Rocca A; Stupp R; Kovács AF; Amellal N; Bessa EH; Bourhis J
    Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):418-24. PubMed ID: 16149284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.